Safety of anti-vegf: endophthalmitis

Peter Kaiser, MD

Peter K. Kaiser, MD discusses the distinction between infectious and non-infectious endophthalmitis and why making the correct diagnosis is critical to determining the proper therapy. He also presents the results of studies that show the incidence of both types of endophthalmitis following EYLEA^® intravitreal aflibercept injection as well as how the incidence rate compares to Lucentis® intravitreal ranibizumab injection.

Posted: 9/29/2015